1 / 19

Biotechnology 2

Biotechnology 2. Kurt Wilkinson • Melody Wang • Jesse Yang • Si Shen. Outline . Background Current News Ratios Future Growth. Background. Incorporated 1987 in Delaware Headquartered in Foster City, CA Operations in Europe, North America and Asia Pacific 5,000 Employees. Background.

vlora
Download Presentation

Biotechnology 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biotechnology 2 Kurt Wilkinson • Melody Wang • Jesse Yang • Si Shen

  2. Outline • Background • Current News • Ratios • Future Growth

  3. Background • Incorporated 1987 in Delaware • Headquartered in Foster City, CA • Operations in Europe, North America and Asia Pacific • 5,000 Employees

  4. Background • Focuses on antiviral drugs • HIV treatment • Hepatitis A/B • Hepatitis C • Also produces treatment for metabolic and respiratory conditions

  5. Background - Products HIV/AIDS • Atripla • Truvada • Viread • Complera/Eviplera • Emtriva LIVER DISEASE • Viread • Hepsera • CARDIOVASCULAR • Letairis • Ranexa • Lexiscan/Rapiscan • RESPIRATORY • Cayston • Tamiflu • OTHER • AmBisome • Vistide • Macugen

  6. Background • Named one of the fastest growing companies by Fortune in 2009 • Named one of America’s best companies to work for by Forbes in 2009 • Supplies 1/3 of the HIV medication used in the developing world

  7. Mergers and Acquisitions • 1999: Nexstar Pharmaceuticals • 2003: Triangle Pharmaceuticals • 2006: Corus Pharma, Inc • 2006: Myogen, Inc • 2006: Raylo Chemicals, Inc. • 2007: Nycomedfr. Altana – Cork • 2009: CV Therapeutics, Inc • 2010: CGI Pharmaceuticals • 2010: Arresto Biosciences, Inc • 2011: Carlistoga Pharmaceuticals • 2012: Pharmasset

  8. Subsidiaries • Gilead Sciences GmbH Germany • Gilead Sciences Hellas EPE Greece • Gilead Sciences Holding, LLC United States • Gilead Sciences Hong Kong Limited Hong Kong • Gilead Sciences International Ltd. United Kingdom • Gilead Sciences Korea Limited South Korea • Gilead Sciences Lda. Portugal • Gilead Sciences Limited Ireland • Gilead Sciences llacTicaret Limited Sireketi Turkey • Gilead Sciences Ltd. United Kingdom • Gilead Sciences Luxembourg S.a.r.l. Luxembourg • Gilead Sciences Netherlands BV Netherlands • Gilead Sciences Norway AS Norway • Gilead Sciences Poland Sp. Z o.o Poland • Gilead Sciences Pty Limited Australia • Gilead Sciences S.L. Spain • Gilead Sciences S.r.l. Italy • Gilead Sciences SAS France • Gilead Sciences Sweden AB Sweden • Gilead Sciences Switzerland Sarl Switzerland • Pharmasset UK Limited United Kingdom • Tri-Supply Limited Ireland • Bristol-Myers Squibb and Gilead Sciences Limited Ireland • Bristol-Myers Squibb & Gilead Sciences, LLC United States • Gilead Alberta ULC Canada • Gilead Alberta, LLC United States • Gilead Biologics, Inc. United States • Gilead Biopharmaceutics Ireland Corporation Ireland • Gilead Calistoga, LLC United States • Gilead Colorado, Inc. United States • Gilead Connecticut, Inc. United States • Gilead Holdings, LLC United States • Gilead Oncology Ireland Ltd Ireland • Gilead Palo Alto, Inc. United States • Gilead Pharmasset LLC United States • Gilead Sciences (NZ) New Zealand • Gilead Sciences Belgium BVBA Belgium • Gilead Sciences Canada, Inc. Canada • Gilead Sciences Cork Limited Ireland • Gilead Sciences Denmark ApS Denmark • Gilead Sciences Europe Ltd. United Kingdom • Gilead Sciences Finland Oy Finland • Gilead Sciences GesmbH. Austria

  9. Current News – Hepatitis C Treatment Hepatitis C drug “sofosbuvir” awaiting FDA approval • Acquired Pharmasset for $11.2 billion in 2012, which already had extensive R&D in Hepatitis C • Pharmasset’s market price increased by 278% from 2007 to 2011 due to the value of their R&D • Sofosbuvir already passed four Phase III trials • No vaccine currently available, easier to administer, fewer side-effects than other treatments • Hepatitis C drug could generate as much as $3.8 billion in sales per year by 2020 (Bloomberg)

  10. Ratios: Liquidity

  11. Ratios: Efficiency

  12. Ratios: Leverage

  13. Ratios: Profitability – Profit Margins

  14. Ratios: Profitability/Market * Due to a stock split in January, the weighted average shares outstanding is not accurate

  15. Other – R&D as a % of Revenue • Generally, a low ratio means good returns on research and development expenses. • However, if too low, the company may not be investing enough in R&D for future sales.

  16. Future Growth • Shares rose by 79% in 2012 (Bloomberg) • 26 out of 32 analysts on Bloomberg rate GILD stock as a “buy” • Analysts expect revenue to be 9.20% higher in 2013 than 2012 • Hepatitis C drug could generate as much as $3.8 billion in annual sales by 2020 (Bloomberg) • Additionally, four HIV/AIDS drugs and one for heart failure are in final stages of testing

  17. Sales of Gilead’s Top 2 HIV Treatments

  18. Stock Growth

  19. Stock Growth vs. Other HIV/AIDS Companies (NYSE)

More Related